ArabFinance: GlaxoSmithKline (GSK Egypt) (BIOC) reported a consolidated net profit of EGP 70.13 million during the first nine months of 2021, compared to EGP 101.39 million in the corresponding period of 2020, according to the companys filing to the Egyptian Exchange.

The companys standalone net profit reached EGP 20.64 million during the January-September period of 2021, compared to EGP 115.9 million in the same period last year.

During the first half of 2021, the company posted a consolidated net profit before minority interest of EGP 20.64 million.

GSK Egypt, a member of the British pharmaceutical company Glaxo Group, is an Egypt-based company engaged in the manufacture, packaging, marketing, sale, and distribution of pharmaceutical products.

Copyright 2021 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an as is and as available basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.